Table 5.
Cox multivariate analysis of TP53 and MIPI in relation to overall and event free survival in the MCL2/3 cohort.
| Patients (n) | HR | 95% CI | P-value* | |
|---|---|---|---|---|
| Overall survival | ||||
| TP53weak/intermediate | 82 | 1·0 | ||
| TP53strong | 10 | 6·4 | 2·6–16·1 | <0·001 |
| MIPI (continuous) | 92 | 3·6 | 2·3–5·6 | <0·001 |
| Event-free survival | ||||
| TP53weak/intermediate | 82 | 1·0 | ||
| TP53strong | 10 | 6·1 | 2·8–13·4 | <0·001 |
| MIPI (continuous) | 92 | 3·0 | 1·9–4·6 | <0·001 |
HR, hazard ratio; 95% CI, 95% confidence interval; MIPI, Mantle cell lymphoma International Prognostic Index.
*
Statistical significant P-values are shown in bold.